Many cancer drugs remain unproven 5 years after accelerated approval, a study finds

Researchers have found that most cancer drugs granted accelerated approval by the U.S. Food and Drug Administration do not deliver on their early promise. The program allows the FDA to

Related Keywords

United States ,Houston ,Texas ,San Diego ,California ,American ,Edward Cliff ,Ezekiel Emanuel ,Jennifer Litton ,Cherie Duvall Jones ,American Association For Cancer Research ,Harvard Medical School ,Md Anderson Cancer Center ,Educational Media Group ,Science Department ,Howard Hughes Medical Institute Science ,Drug Administration ,University Of Pennsylvania ,Journal Of The American Medical Association ,American Medical Association ,American Association ,Cancer Research ,Harvard Medical ,Cancer Center ,Associated Press Health ,Howard Hughes Medical Institute ,Educational Media ,